rope03 rope02 rope02

A Turning Point for Precision Oncology

Targeted cancer therapies designed to address treatment resistance and improve lives.

Helping patients stay on their treatment path longer

Kinase inhibitors eventually develop resistance. Our drug candidates are structurally different and address the key limitations of existing therapies.

Founded and Led by Pioneers of Precision Medicine

Turning Point Therapeutics has assembled an experienced team to discover and develop next-generation cancer treatments with greater potency and potentially improved efficacy over existing kinase inhibitors.

ltBlueRP03 ltBlueRP02left ltBlueRP02left

Clear Potential to Improve Cancer Treatment

Our registration-enabling study of lead drug candidate, repotrectinib, is currently open for enrollment of patients with non-small cell lung cancer and advanced solid tumors harboring oncogenic driver fusions.

We believe we’ve discovered a way to overcome one of the greatest limitations of today’s targeted cancer treatments, and we’re working to bring it to patients as quickly as possible.

-Athena Countouriotis, M.D., President and CEO

Copyright © 2019 Turning Point Therapeutics, Inc. | All Rights Reserved